Amplia Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Amplia Therapeutics şirketinin toplam hissedar öz sermayesi A$11.4M ve toplam borcu A$1.5M olup, bu da borç-öz sermaye oranını 13.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$14.8M ve A$3.4M dir.

Anahtar bilgiler

13.1%

Borç/özkaynak oranı

AU$1.49m

Borç

Faiz karşılama oranı	n/a
Nakit	AU$3.39m
Eşitlik	AU$11.42m
Toplam yükümlülükler	AU$3.43m
Toplam varlıklar	AU$14.85m

Son finansal sağlık güncellemeleri

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Jan 13

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Apr 28

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Jan 06

Recent updates

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Jan 13

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Apr 28

Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings

Feb 28

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Jan 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ATX 'nin kısa vadeli varlıkları ( A$6.8M ) kısa vadeli yükümlülüklerini ( A$3.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: ATX şirketinin kısa vadeli varlıkları ( A$6.8M ) uzun vadeli yükümlülüklerini ( A$23.4K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ATX şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: ATX şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 13.1% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ATX son raporlanan serbest nakit akışına göre 8 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: ATX serbest nakit akışı tahminlerine göre 8 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Amplia Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Amplia Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Recent updates

Amplia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.9 million.

Amplia Therapeutics Limited, Annual General Meeting, Aug 23, 2024

New minor risk - Shareholder dilution

Amplia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.27 million.

Amplia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.27 million.

Amplia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.27 million.

New major risk - Market cap size

Amplia Therapeutics Limited Announces FDA Clearance of it's IND for Pancreatic Cancer Trial in US

New major risk - Financial position

New major risk - Market cap size

Amplia Therapeutics Limited Announces Chief Financial Officer Changes

New major risk - Market cap size

New major risk - Market cap size

Amplia Therapeutics Limited, Annual General Meeting, Aug 24, 2023

Amplia Receives Grant to Collaborate with CSIRO

Amplia Therapeutics Limited Announces Dose Escalation Approved in ACCENT Clinical Trial of AMP945

Amplia Therapeutics Limited Appoints Christopher Burns as Managing Director, Effective December 5, 2022

Amplia Therapeutics Limited Announces CEO Changes

Amplia Therapeutics Limited Announces First Patient Recruited to ACCENT Trial in Pancreatic Cancer

Amplia Therapeutics Limited, Annual General Meeting, Aug 25, 2022

Amplia Therapeutics Limited Shows AMP945 Efficacy in Model of Lung Fibrosis

Amplia Therapeutics Limited Receives Second Ethics Clearance for Phase 2 Trial

Amplia Therapeutics Limited Receives Human Research Ethics Committee Approval to Initiate Phase 2 Clinical Trial of Its Focal Adhesion Kinase Inhibitor, AMP945

Amplia Therapeutics Limited Completes Manufacture of AMP945 for Planned Trials

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Non-Executive Director recently bought AU$104k worth of stock

Chief Financial Officer Jeff Carter has left the company

Amplia to Conduct Phase 2 Trial in First-Line Pancreatic Cancer Patients

Non-Executive Director recently bought AU$122k worth of stock

Amplia Therapeutics Limited Announces Results from Successful Phase 1 Clinical Trial of Amp945

Amplia Therapeutics Limited Receives New Data from its Collaboration with Professor Paul Timpson of the Garvan Institute of Medical Research, Sydney

Amplia Therapeutics Limited announced that it expects to receive AUD 3.81455 million in funding from Platinum Investment Management Limited, Blueflag Holdings Pty Ltd, Acorn Capital Limited, and other investors

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Amplia Therapeutics Limited Completes Single Dose Study of AMP945

Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings

Amplia Therapeutics Limited Initiates Multiple Dose Study of AMP945

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

New 90-day high: AU$0.22

Amplia Therapeutics Limited Announces First Human Dose in Phase 1 Clinical Trial of AMP945

Amplia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 3.987791 million.

Amplia Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin